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IMPROVED TARGET COVERAGE OF SPINAL METASTASES THROUGH THE 
USE OF FLATTENING FILTER FREE BEAMS 
 
Laura Christine Bennett, B.S. 
Advisory Professor: Oleg Vassiliev, Ph.D. 
 
   Of the patients that are diagnosed with metastatic disease, up to 40% will 
develop vertebral osseous metastases. These metastases tend to be located in close 
proximity to the spinal cord itself, making it difficult to achieve the recommended 
minimum dose of 14 Gy for single fraction SBRT or 21 Gy1 for three fraction SBRT 
while maintaining acceptable doses to the cord and cauda equina. This proximity of the 
target to critical structures has the potential to compromise the efficacy of the radiation 
treatment plan in favor of reducing normal tissue dose, resulting in poor local control and 
tumor recurrence at follow-up. Flattening Filter Free (FFF) photon beams have been 
shown to have lower out-of-field dose and sharper dose gradients when compared with 
conventionally flattened (FF) photon beams of similar energy; this sharp dose fall-off  
could potentially prove beneficial in cases where greater precision is required, such as 
for high-dose hypofractionated radiation treatments of vertebral metasases. The purpose 
of this project was to compare the physical properties, namely penumbral width and 
penumbral and out-of-field dose of FFF and FF photon beams as well as determine the 
clinical effects of these beams on vertebral osseous tumors. It was hypothesized that FFF 
beams would show a definitive improvement in target coverage while maintaining 
acceptable normal tissue doses when compared with FF beams. To test this hypothesis, 
penumbral width and dose were measured for FF and FFF beam profiles at various 
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depths and field sizes using the Varian Standard Beam Data by examining the treatment 
plans for twelve patients with spine metastases using both FF and FFF beams. There was 
a statistically significant reduction in penumbral width for FFF plans when compared to 
FF plans; however, this difference was in effect quite small and may not translate into 
better treatment plans. There was no demonstrable difference between treatment plans 
developed using FF or FFF beams in terms of minimum dose to the GTV. However, 
there was significant reduction in treatment delivery time for FFF plans, which may  lead 
to reduced intrafractional variation from patient motion and a more positive patient 
experience.
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1  INTRODUCTION 
 
1.1 – Spine Metastases 
1.1.1 – Prevalence of Spine Metastases 
 Of all patients that are diagnosed with metastatic cancer each year, it is 
estimated that 40% will develop metastases in the spinal column, and of those who 
eventually die due to cancer, up to 70% will have spinal metastases at the time of death2–
5. Often, these patients may experience pain, incontinence, or loss of ambulatory 
function due to compression of the spine – a complication that occurs in up to 20% of 
patients with spine metastases6. The recommended treatment in these cases is often a 
combination of therapies including surgical resection of the tumor and radiation 
therapy7. 
1.1.2 – Standard Treatments and Typical Patient Outcomes 
 Patients undergoing radiotherapy for spinal cord lesions either adjuvant with 
surgery or as a stand-alone treatment often receive stereotactic body radiation therapy 
(SBRT). Standard fractionation external-beam radiotherapy (EBRT) is typically 
scheduled as 1.8-2.0 Gy delivered 5 days per week for up to 8 weeks8. In comparison, 
SBRT treatments typically include prescriptions doses of 24-30 Gy over a course of 1-5 
fractions9. This is most often the preferred method of radiation therapy due to the 
sensitivity of the spinal cord to radiation and the proximity of the tumor to the cord 
itself; in such cases, hypofractionated, high dose radiation is favored in order to limit 
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normal tissue dose while delivering adequate radiation to the target.  In order to 
minimize dose to healthy tissue (spine, lungs, kidney, etc.) while maintaining target 
coverage and prescription dose constraints, a large number of convergent beams are 
directed at the target to maximize dose around the gross tumor volume (GTV)10. In most 
cases, some sort of immobilization device such as a vac-loc bag or thermoplastic cast is 
used to limit intrafractional motion during treatment11. Additionally, image-guided 
tracking in the form of a combination of CT and MRI  is used in almost all cases to limit 
intrafractional motion during treatment11,12. 
Outcomes for patients undergoing SBRT for spinal metastases are typically 
positive. A study by Zelefsky et al13 in 1992 examining patients undergoing radiation 
treatment of the spine reported that 92% who completed treatment experienced pain 
relief; another study by Yamada et al14 examining high-dose hypofractionated IMRT for 
spinal metastasis in 93 patients showed 90% local control at 15 months post therapy. 
Ahmed et al15 treated eighty-five spinal lesions using SBRT; local control at 12 months 
was 83.3% and 91.2% for patients with and without prior radiotherapy respectively. 
Local control is more likely for these patients when a minimum “threshold dose” 
is met in the GTV; an investigation of 285 patients with spinal metastases treated with 
SBRT by Bishop et al found that local control was more likely with higher GTV 
minimum dose (Dmin) and recommended that patients undergoing a single fraction 
course receive at least 14 Gy to the GTV Dmin while those undergoing a three fraction 
course should receive at least 21 Gy to the GTV Dmin1. Unfortunately, spine metastases 
are often located close to the cord itself –often within a millimeter or less - making it 
difficult to meet the thresholds necessary to establish tumor local control without 
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imparting excessive dose to the cord or cauda equina16,17. Due to the risk of permanent 
radiation myelopathy, many physicians may be forced to limit dose to the GTV in order 
to maintain clinically acceptable doses to the cord, reducing the overall efficacy of 
treatment18.  
1.2 – Flattening Filter Free Beams 
1.2.1 – Characteristics of Flattening Filter Free Beams 
 In recent years, manufacturers of medical linear accelerators (linacs) have 
begun to produce machines capable of producing beams in Flattening Filter Free (FFF) 
mode. Traditionally, photon beams use a metal flattening filter (FF) in order to produce 
dose profiles with uniform photon intensity across the field; FFF beams are the result of 
removing the flattening filter, creating a more “peaked” dose distribution19,20. FFF beams 
were originally conceived for use with fluence-modifying devices such as multi-leaf 
collimators for IMRT, where smaller average field sizes make a large, uniform dose 
distribution unnecessary21. 
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Figure 1-1: Profiles for FFF (red) and FF (blue) beams; FFF profile is noticeably more "peaked" 
 
 
 Compared to traditionally flattened beams, FFF beams have a number of 
unique characteristics, the first and most obvious being the singular shape of their dose 
distributions: unlike FF beams, FFF beams are marked by high fluence in the center of 
the field with steep fall-off at the field edges22. The sharper dose gradient is likely a 
function of the demonstrated reduction in head scatter, electron contamination, and 
overall out-of-field dose common to FFF beams due to elimination of the filter23–25. An 
additional benefit of FFF beams is their ability to deliver the same prescription as FF 
beams at a significantly higher dose rate, allowing beam-on time to be greatly 
reduced26,27 while reducing the amount of scatter generated. The resultant reduction in 
treatment time is highly beneficial for treatments wherein high precision is essential, as it 
limits the potential for intrafractional motion to create unacceptable errors28,29.\ 
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1.2.2 – Biology and Physics of Flattening Filter Free Beams 
  
 There is a reasonable biological component as to why FFF should be 
considered over FF beams: to begin with, the softer energy spectrum of FFF may result 
in a higher relative biological effectiveness (RBE). A traditional FF beam has a much 
harder spectra due to the selective removal of lower energy photons by the flattening 
filter. This results in a beam that is more penetrating, but has a lower linear energy 
transfer (LET). A softer beam produces lower energy electrons in the medium, resulting 
in a higher LET and therefore a higher RBE30. Additionally, the increased dose rate of 
FFF beams may have an effect on tumor cell survival. Radiosensitivity is reduced at low 
dose rates, as intracellular repair may begin to take place for longer treatment times, as 
the half-time for repair may be less than one hour31.   
For vertebral osseous tumors, energy deposition varies with respect to other 
types of tissue (muscle, fat). Bone has a higher average atomic number than normal 
tissues at 12.31 kg/m3 versus 7.64 kg/m3 for muscle, 6.46 kg/m3 for fat, or 7.51 kg/m3 
for water32. At lower energies, this results in a higher probability for interaction via the 
photoelectric effect which has a high Z dependence, resulting in greater dose 
deposition in bone. However, this is more of a concern at diagnostic energies (30-150 
keV) than therapeutic energies (6-18 MeV), as the cross section of the photoelectric 
effect is inversely proportional to photon energy. Instead, the Compton effect 
predominates at therapeutic energy levels and effectively determines dose in this 
range. Unlike the photoelectric effect, which has a strong dependence on the Z of the 
material, the Compton effect is primarily dependent on electron density. Bone, having 
a lower electron density than water (3.192 x 1026 elect/kg versus 3.343 x 1026 
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elect/kg), is subject to fewer Compton interactions and thus has slightly lower energy 
deposition than other tissues32. 
Physically, the removal of the flattening filter is associated with a reduction in 
out-of-field dose. This is primarily a function of the elimination of the flattening filter 
as a source of scatter23 as well as the improvement in delivery efficiency resulting in 
reduced head leakage22. 
 
 
 
1.2.3 – Prior Studies 
 There are a number of extant studies that have investigated the physical 
properties of FFF beams as well as their clinical implications. A research group at MD 
Anderson Cancer Center published three studies in 2006 examining the dosimetric 
properties of FFF beams; backscatter, depth dose profiles, lateral dose profiles, MLC 
leakage, total scatter factor, and dose rate were investigated and compared with 
conventional FF beams33–35. In later studies by Kry et al at MD Anderson Cancer 
Center23 and Almberg et al at the Norwegian University of Science and Technology25, 
out-of-field dose produced by FFF beams was examined using Monte Carlo simulations; 
both groups determined that FFF showed clinically relevant reductions in out-of-field 
dose when compared with FF beams of similar energy. 
 Treatment planning studies examining FFF beams in a clinical setting have 
been carried out cancers in a variety of sites, including prostate36–38, lung39–41, liver42,43, 
and brain44,45. Studies on the effect of FFF-based treatments on spinal column – where 
the potential for increased precision from reduction in out-of-field dose, treatment time, 
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and head scatter would prove to be of great benefit due to the proximity of tumors to the 
spinal cord – are somewhat limited in number and scope. A study by Ong et al conducted 
in 2012 investigated the impact of FFF beams compared with FF beams using RapidArc 
delivery of SBRT treatments of vertebral bodies in order to determine the effect of the 
reduction in treatment time demonstrated by FFF beams on intrafractional shifts46. The 
results of the study indicated that dosimetric variations were greater for FFF plans due to 
the significantly higher dose rate; however, these results may be complicated by the fact 
that the energies examined for each beam – 6 MV for FF and 10 MV for FFF – 
introduced differences in the dosimetric properties of each beam such that direct 
comparison of the two would be difficult. Additionally, the probability of an 
intrafractional shift occurring during a given treatment is lower for FFF beams due to the 
much shorter beam-on time, a factor that was not considered by this study. Another 
study investigating the effect of FFF beams in IMRT and VMAT treatments of spinal 
column metastases where prior radiotherapy had been performed was undertaken by 
Dobler et al in 2016 compared target coverage and spinal cord dose between FF and FFF 
plans. This study demonstrated significant improvement for FFF beams in normal tissue 
sparing and dose homogeneity47. No studies have been found to examine the effect of 
FFF beams on minimum dose (Dmin) to the GTV in spine metastases. Due to the limited 
number of fractions in SBRT treatments of spine tumors, ensuring that a threshold dose 
is met is necessary to ensure that local control is maintained; Bishop et al have found 
that Dmin should be at least 14 Gy for single-fraction, 24 Gy plans or at least 21 Gy for 
three-fraction, 27 Gy plans to limit the risk of recurrence at follow-up1. The current 
study was undertaken to evaluate the effects of FFF beams on GTV Dmin and determine 
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the feasibility of using FFF beams in stereotactic radiotherapy for spinal column 
metastases.  
1.3 – Hypothesis and Specific Aims 
We hypothesize that a clinically significant reduction in out-of-field and penumbral 
dose such that improved tumor coverage is achieved may be accomplished through the 
use of Flattening Filter Free (FFF) photon beams given their unique dosimetric profile 
and that FFF beams will generate treatment plans that are clinically equivalent to those 
plans developed using FF beams. The hypothesis was tested with the following specific 
aims: 
1.  Examine and characterize the difference in penumbral and peripheral dose 
between Flattening Filter Free beams and conventionally flattened beams of similar 
depth-dose distributions. This aim shall be done by examining beam profile data for 
both FFF and FF beams provided by Varian (Varian Representative Data) as well as 
Monte Carlo generated data. The FF beams will be normalized by central axis dose (or 
some nominal percentage thereof); the FFF beams will be normalized to 110% at the 
central axis for FF profiles and the dose of the FFF profile at the point of 100% dose on 
the FF profile in order to account for the different shapes of the two profiles and make a 
more fair comparison of peripheral dose. After normalization, we intend to calculate and 
compare penumbral widths (the distance between 80%-20% maximum dose) and the 
relative dose at varying distances from the field edge (0.5-20 mm from 50% central axis 
dose). 
  
9 
 
2. Develop and compare treatment plans using FFF and FF beams. This shall be 
done using the ECLIPSE treatment planning system and the Varian Representative Data. 
We intend to pre-existing plans generated in Pinnacle for 12 unique patients with spinal 
metastases, and compare them to plans generated using the Varian Representative Data 
for FFF beams. We will be using the Acuros XB Advanced Dose Calculation algorithm 
in the ECLIPSE treatment planning system in order to achieve maximum accuracy, as 
this project aims to examine high dose gradients, heterogeneities, and out-of-field doses, 
all of which are best modeled using Acuros XB. The same dosimetric constraints will be 
used to normalize the plans in order to make a fair comparison of the plans. Parameters 
to be investigated will include minimum dose to the GTV, D0.03cc to the spinal cord and 
cauda equina, beam-on time, and total machine units. 
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2  MATERIALS AND METHODS 
 
2.1 – Analysis of Dose Profiles 
2.1.1 – Varian Standard Beam Data 
 Prior to developing treatment plans, we first analyzed the dose profiles for FF 
and FFF beams provided in the Varian Standard Beam Data (Varian Medical Systems 
Inc, Palo Alto, CA) - previously the Varian Golden Beam Data - from which we would 
be developing beam models for the treatment planning system. The Varian Standard 
Beam Data contains Percent Depth Dose (PDD) and dose profile measurements of a 
standard Varian TrueBeam for a number of different field sizes and beam energies. 
These measurements were taken using an IBA Dosimetry CC13 ionization chamber in a 
3D water phantom in step sizes of 1 mm. We compared dose profiles of 6 MV FF and 6 
MV FFF beams at depths of 5 cm, 10 cm, 20 cm, and 30 cm and at field sizes of 3x3 
cm2, 4x4 cm2, 8x8 cm2, and 10x10 cm2. Penumbral width – defined here as the distance 
between the 80% maximum dose point and the 20% maximum dose point – and relative 
dose at 2 mm, 5 mm, 10 mm, 30 mm, and 50 mm from the field edge were reviewed.  
For this study, absolute difference between penumbral width and penumbral and out-of-
field dose for FF and FFF beam profiles were assessed and evaluated by Wilcoxon 
Signed Rank test.  
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2.1.2 – Normalization of Profiles 
 Due to the difference in shapes between FF and FFF dose profiles, it is 
necessary to renormalize each beams in order to make comparison of the penumbral 
width more objective. As of this study, there is no standard for this normalization, 
though a number of techniques have been used. Pönisch et al. suggested using the 
inflection point at the field edge34. This method, though intuitive, has the disadvantage of 
introducing a large degree of uncertainty due to the need for incredibly granular 
measurements in a high gradient region; often, measurements are taken with no less than 
1 mm separation for quality assurance, limiting precision and imposing a minimum 
degree of uncertainty into dose profile measurements48. Fogliata et al. favored using a 
separate “renormalization point” to determine the normalization factor. A shoulder point 
could be found by calculating the third derivative of the FF beam in the penumbra region 
and using the second maximum to normalize the FFF beam to the same point48. Since 
this study was primarily focused on the effects of the different beams on SBRT 
treatments, we elected to normalize FF and FFF beams as described here: FF beams were 
normalized such that central axis dose was 110% maximum dose. The location of 100% 
maximum dose on the FF profiles was then marked; FFF beams were normalized 
according to the relative dose of the FFF beams at that location. This method of 
normalization controlled the profile shapes effectively while keeping the dose 
distribution within the treatment field within clinically acceptable limits. Figure 2-1 
below depicts the two beam profiles before and after normalization.   
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Figure 2-1: Dose profiles before and after normalizing. On the left is the raw beam data (normalized to 100% max dose 
on the central axis); on the right is the renormalized data (FF normalized to 110% dose, FFF normalized to FFF dose at 
location of 100% dose on FF profile). 
 
2.2 – Treatment Planning 
 2.2.1 – Patient Population 
 A cohort of 12 patients previously treated for spinal metastases at MDACC 
were selected for this study. Of these, four had tumors in the cervical region of the spinal 
cord, three in the thoracic region, and five in the lumbar region. Half of these patients 
were prescribed 24 Gy in a single fraction by a radiation oncologist; the other half were 
prescribed 27 Gy in three fractions. The entire patient population is summarized in Table 
2-1 below.  
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Table 2-1: Summary of patient population by site, prescription dose, and number of fractions. 
Patient 
# 
Site 
Prescription, 
Gy 
# of 
fractions 
1 L1-L2 24 1 
2 T1 24 1 
3 L2 24 1 
4 T10 24 1 
5 L2 24 1 
6 L4 24 1 
7 C2 27 3 
8 C7 27 3 
9 C4 27 3 
10 T2-T4 27 3 
11 C5-C6 27 3 
12 L5-S1 27 3 
 
 Epidural spinal cord compression grading (ESCC), also known as the Bilsky 
score, was used to determine suitability of patients for SBRT treatment and prescription 
dose and normal tissue dose constraints. The Bilsky system defines 6 stages of cord 
compression, with Grade 0 defining bone-only disease, Grade 1 defining epidural 
impingement (with three stages describing degree of impingement), Grade 2 cord 
compression with visible cerebrospinal fluid (CSF) still visible, and Grade 3 cord 
compression without visible CSF49. Complete definitions are summarized in Table 2-2 
below.  
 Spine SBRT is recommended for cases with a Bilsky grade of 0-1; higher 
Bilsky grades (2-3) are indicative of a need for high caution or unsuitability of SBRT 
due to the proximity of the tumor to cord50. Grades 2-3 often require surgical 
decompression before SBRT may be considered. Cases where the tumor volume is quite 
large or has been previously irradiated are more typically prescribed a higher number of 
fractions (27 Gy in 3 fractions versus 24 Gy in a single fraction)50.  
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Table 2-2: ESCC/Bilsky Grading Scale 
Bilsky Score Definition 
Grade 0 • Bone only 
Grade 1a 
• Epidural impingement, no 
deformation of thecal sac 
Grade 1b 
• Epidural impingement, 
deformation of thecal sac, no 
spinal cord abutment 
Grade 1 c 
• Epidural impingement, 
deformation of thecal sac, 
spinal cord abutment, no 
cord compression 
Grade 2 
• Cord compression with 
visible cerebrospinal fluid 
(CSF) around cord 
Grade 3 
• Cord compression without 
visible CSF around spinal 
cord 
 
GTV volume for each patient is summarized below; average volume for all twelve 
patients was 21.10 cm3 and ranged from 10.3 cc (Patient 8) to 100.7 cc (Patient 6).   
Table 2-3: GTV Volume (cm3) 
Patient 
ID 
GTV 
Volume (cc) 
24 Gy Single-Fraction 
1 53.2 
2 11.1 
3 50.1 
4 19.7 
5 42.5 
6 100.7 
27 Gy Three-Fraction 
7 22.5 
8 10.3 
9 14.6 
10 62.7 
11 11.1 
12 10.5 
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 2.2.2 – Treatment Planning Parameters 
 For each patient, two treatment plans were developed: one using 6 MV FF 
beam data and the other using 6 MV FFF beam data. The dose rate was set to 600 
MU/min for FF plans; for FFF plans, the dose rate was 1400 MU/min. The maximum 
dose rate was chosen for FFF plans in order to take advantage of the potential reduction 
of beam-on time and resultant lowered integral dose20. For each plan, identical beam 
arrangements were used: for the majority of plans, nine coplaner beams spaced 20° apart 
from 100° to 260° were defined in the treatment planning system (TPS). Figure 2-2 
shows a representative plan. Three patients (Patient 1, Patient 8, and Patient 11) did not 
have this arrangement due to the location of the gross tumor volume relative to the 
respective organs at risk. Multiple Static Segments using 10 segments per field were 
used for plan delivery.  
 
Figure 2-2: Standard beam arrangement for spinal SBRT patients 
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All treatment plans were generated using the Eclipse TPS and the Acuros XB 
dose calculation algorithm (Varian Medical Systems, Palo Alto, CA). Eclipse was 
chosen as the TPS for this study due to the demonstrated ability for Acuros XB – a 
dose calculation algorithm exclusive to Eclipse that utilizes the Linear Boltzmann 
Transport Equation - to accurately account for tissue heterogeneities including FFF 
beams as well as FF beams51,52.  
 
For all patients, plans were developed with the goal of increasing minimum 
dose to the GTV Dmin up to and beyond the recommended threshold for the 
prescription without pushing dose to normal tissue and primary organs at risk (OAR) 
above acceptable levels. For patients receiving 24 Gy in a single fraction, a Dmin of 
at least 14 Gy was attempted; for patients receiving 27 Gy in three fractions, the goal 
was a Dmin of at least 21 Gy. These planning directives were used to maintain 
efficacy of the plans, as doses lower than 14 Gy (single fraction) or 21 Gy (three 
fraction) were found to be associated with decreased local control1. To improve 
comparison between the two sets of plans, dose to the cauda equina (lumbar patients) 
or spinal cord (cervical and thoracic patients) was kept within 5% between FF and 
FFF plans.  
All patients were originally treated at MD Anderson using plans developed in 
the Pinnacle TPS. Plans created for this study utilized the plans, physician planning 
directives, and institutional guidelines (Table 2-2 below) to determine normal tissue 
tolerance and field arrangement. Dmax to the spinal cord was kept below 10 Gy for 
all plans regardless of prescription; Dmax to the cauda equina was kept below 16 Gy 
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or 14 Gy for single- and three-fraction courses, respectively. As most patients had 
received prior irradiation, more conservative dose guidelines were utilized; this 
limited how much dose could be delivered to the target volume, but was necessary to 
limit late effects of radiation on normal tissue volumes had the patients been treated 
with these plans. 
Table 2-4: Institutional Guidelines for Normal Tissue Tolerances 
 Single Fraction Three Fraction 
Organ Volume Dose 
Maximum 
Dose 
Volume Dose 
Maximum 
Dose 
Spinal Cord V(8Gy) ≤ 1cc 10 Gy V(9Gy) ≤ 0.01cc 10 Gy 
Cauda Equina V(10Gy) ≤ 1cc 16 Gy V(12Gy) ≤ 0.1cc 14 Gy 
Esophagus V(12Gy) ≤ 5cc 16 Gy V(12Gy) ≤ 5cc 16 Gy 
Brachial Plexus V(11.9Gy) ≤ 3cc 16 Gy V(15Gy) ≤ 0.01cc 17 Gy 
Heart V(16Gy) ≤ 15cc 22 Gy V(15Gy) ≤ 15cc 21 Gy 
Trachea V(8.8Gy) ≤ 4cc 20.2 Gy V(8.8Gy) ≤ 4cc 18 Gy 
Skin V(14Gy) ≤ 10cc 16 Gy V(16Gy) ≤ 10cc 21 Gy 
Small Bowel V(9Gy) ≤ 5cc 15.4 Gy V(9Gy) ≤ 0.01cc 10 Gy 
Colon V(11Gy) ≤ 20cc 18.4 Gy V(11Gy) ≤ 20cc 18 Gy 
Rectum V(11Gy) ≤ 20cc 18.4 Gy V(11Gy) ≤ 20cc 18 Gy 
Each Kidney V(8Gy) ≤ 2/3 Volume N/A V(10Gy) ≤ 4/5 Volume N/A 
Total Kidney 
V(8.4Gy) ≤ 200cc, 
V(7.4Gy) ≤ 1000cc 
N/A V(10Gy) ≤ 1/5 Volume N/A 
Total Lung V(7Gy) ≤ 1000cc N/A V(10Gy) ≤ 600cc N/A 
Other 
Volume outside PTV(≥100-
110% Prescription) ≤ 1cc 
N/A 
Volume outside PTV(≥100-
110% Prescription) ≤ 8cc 
N/A 
 
Order of plan creation was alternated for each patient such that biases by the 
primary planner were limited – for example, if Patient 1’s planning order was FF 
followed by FFF, then Patient 2’s planning order was FFF followed by FF.  
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2.3 – Statistical Analysis 
 
 
We applied Wilcoxon signed rank test to compare the dose profiles for FF and 
FFF beams and GTV Dmin between the treatment plans. A two-sided p-value of less 
than 0.05 was considered statistically significant. All analyses were performed with 
statistical software R v3.4.3 (Vienna, Austria 2016). 
 
 
  
19 
 
3  RESULTS 
 
3.1 – Analysis of Dose Profiles 
3.1.1 – Penumbral Dose 
Relative dose in the penumbra was compared between FF and FFF plans at 
distances of 2 mm, 5 mm, 10 mm, 30 mm, and 50 mm from the field edge at depths of 
5 cm, 10 cm, 20 cm, and 30 cm at four depths and for five different field sizes. The 
percent difference between FFF and FF was calculated and plotted at 5 cm, 10 cm, 20 
cm, and 30 cm depths, shown respectively in Figures 3-1 thru 3-4.  
The ratio of FFF dose to FF dose ranged from 0.72 to 1.06 with a mean of 
0.971 and a standard deviation of 0.05. The reduction in penumbral dose was found to 
be significant by Wilcoxon Signed Rank Test (p < 0.05). 
 
Figure 3-1: FF (solid lines) and FFF (dashed lines) penumbral dose at 5 cm depth 
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Figure 3-2: FF (solid lines) and FFF (dashed lines) penumbral dose at 10 cm depth 
 
 
Figure 3-3: FF (solid lines) and FFF (dashed lines) penumbral dose at 20 cm depth 
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Figure 3-4: FF (solid lines) and FFF (dashed lines) penumbral dose at 30 cm depth 
 
FFF profiles tended to have lower relative penumbral dose compared to FF 
profiles. This finding was particularly pronounced with smaller field sizes, as the 
reduction tended to be reduced (and, at greater depths, reversed) as field size 
increased.  
 
Figure 3-5: Close up of penumbral doses of FFF and FF beams at 5 cm depth. 
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Figure 3-5 (above) shows the region where the difference between FF and FFF was 
largest for all field sizes at 5 cm depth; this difference was greatest between 5-10 mm 
from the field edge. 
 3.1.2 – Penumbral Width 
 There was an overall decrease in width for FFF beams when compared with 
FF beams for all depths and field sizes with the exception of the 10x10 cm2 field for both 
20 cm depth and 30 cm depth. Reduction in penumbral width ranged from 0.77% to 5.02%. 
Although there was no significant difference in penumbral width within each individual field 
size, the overall reduction in width for all field sizes and depths was significant by Wilcoxon 
signed rank test (p < 0.05). The reduced dose and sharpened penumbra associated with FFF 
beams for fields relevant to spine SBRT treatments motivated continuation with the 
treatment planning to determine the practical effect of reduced penumbral width on our 
patient population.  
 
 
Table 3-1: Difference (mm) in penumbral width of FFF beams relative to FF beams in water at various depths (cm) 
 
Depth in Water Phantom   
Field Size (cm2) 5 10 20 30 p-value 
3x3 -0.16 -0.11 -0.27 -0.19 0.0625 
4x4 -0.10 -0.22 -0.14 -0.13 0.0625 
6x6 -0.16 -0.21 -0.15 -0.23 0.0625 
8x8 -0.20 -0.12 -0.10 -0.07 0.0625 
10x10 -0.23 -0.04 0.04 0.22 0.563 
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3.2 – Comparison of Treatment Plans 
Dmin for the GTV for each treatment plan was compared between FF and FFF 
plans. The DVH median and interquartile range were calculated and plotted for single- 
and three-fraction plans (Figure 3-6 A, B). Median dose was higher for FFF plans in the 
single-fraction set (Figure 3-6A) and lower for FFF plans in the three-fraction set (Figure 
3-6B); however, overall differences were not statistically significant.  
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Figure 3-6: Median DVHs for single-and three-fraction GTV 
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Median DVHs were also calculated and plotted for spinal cord (Figure 3-
7A) and cauda equina (Figure 3-7B). This analysis was performed to ensure that 
there was no significant difference in OAR dose in order to better compare GTV 
Dmin for each plan. The median dose was nearly identical at all points of the 
DVH for both cauda equina and spinal cord. Interquartile spread was quite wide 
for the cauda equina DVH; however, this finding is attributed to the fact that the 
cauda equina was the primary OAR for both single- and three-fraction plans, for 
which the max dose limit differed by 2 Gy (16 Gy and 14 Gy for single- and 
three-fraction plans, respectively). The spinal cord DVH interquartile spread was 
tighter, as maximum cord dose was the same regardless of fraction number.  
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Figure 3-7: Cauda and Cord Median DVH 
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 GTV Dmin was calculated and compared for both FF and FFF plans. Six of 
the twelve plans demonstrated an increase in Dmin for FFF plans. The increase in 
Dmin dose was not found to be significant by Wilcoxon Signed Rank Test (p = 0.17). 
The results are summarized below in Table 3-2. 
 
Table 3-2: GTV Dmin for FF and FFF Plans 
Minimum GTV Dose 
 FF FFF % Difference 
24 Gy Single-Fraction 
Patient 1 11.98 10.81 10.21% 
Patient 2 10.34 10.63 2.73% 
Patient 3 15.78 15.81 0.21% 
Patient 4 10.73 10.31 3.91% 
Patient 5 22.45 21.07 6.35% 
Patient 6 13.82 14.15 2.34% 
27 Gy Three-Fraction 
Patient 7 7.30 8.43 14.46% 
Patient 8 16.49 15.73 4.73% 
Patient 9 9.05 8.93 1.33% 
Patient 10 9.73 9.28 4.75% 
Patient 11 8.16 8.19 0.35% 
Patient 12 20.84 21.89 4.90% 
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OAR0.03cc was also calculated for each plan to ensure that dose for the spinal cord or 
cauda was within 5% for FF and FFF plans. The results are listed below in Table 3-4. It 
is worth noting that although these were the primary OAR, the cord and/or cauda equina 
did not define the end-point of planning. All normal tissue limits were observed. As 
such, planning was often considered complete not when maximum primary OAR dose 
was met, but when other normal tissue began to exceed dose constraints, leading to a 
lower than expected GTV dose.  
Table 3-3: OAR0.03cc 
OAR0.03cc 
 Primary 
OAR 
FF FFF % Difference 
24 Gy Single-Fraction 
Patient 1 Cauda 12.6 12.1 4.05% 
Patient 2 Cord 7.4 7.6 2.67% 
Patient 3 Cauda 12.6 12 4.88% 
Patient 4 Cord 7.7 7.6 1.31% 
Patient 5 Cauda 15.2 15.1 0.66% 
Patient 6 Cauda 13.7 14.2 3.58% 
27 Gy Three-Fraction 
Patient 7 Cord 5.95 5.7 4.29% 
Patient 8 Cord 5.6 5.8 0.00% 
Patient 9 Cord 7.95 8 0.63% 
Patient 10 Cord 8.8 8.6 2.30% 
Patient 11 Cord 7.4 7.45 0.67% 
Patient 12 Cauda 6.4 6.45 0.00% 
 
 Beam-on time was also evaluated for each plan, as the duration of treatment 
may have an effect on integral dose. Namely, shorter treatment times limit the potential 
for intrafractional error due to patient motion. Beam on-time per fraction was calculated 
as the dividend of total MU divided by the dose rate (600 MU/minute for FF, 1400 
MU/minute for FFF). Treatment duration was definitively lower for FFF plans compared 
with FF plans (p-value < 0.05). The average reduction in beam-on time was 12.5 
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minutes, with the largest difference being a reduction of 27.8 minutes (Patient 6) and the 
smallest being a reduction of 1.73 minutes (Patient 11). The beam-on time per fraction is 
summarized below in Table 3-5. 
 
 
Table 3-4: Beam-on time per fraction 
Beam-on Time 
FF FFF 
24 Gy Single-Fraction 
Patient 1 23.16 15.39 
Patient 2 23.26 9.48 
Patient 3 47.29 19.58 
Patient 4 44.47 19.85 
Patient 5 21.49 9.84 
Patient 6 42.52 14.74 
27 Gy Three-Fraction 
Patient 7 9.54 3.8 
Patient 8 10.78 5.12 
Patient 9 5.52 2.57 
Patient 10 22.64 12.08 
Patient 11 8.84 7.11 
Patient 12 11.64 1.98 
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Total MUs for each patient plan were calculated and have been recorded below in 
Table 3-6.  
 
Table 3-5: Total MUs for each patient plan 
Total MUs 
Patient 
ID 
FF FFF 
24 Gy Single-Fraction 
1 13896 21543 
2 13958 13278 
3 28372 27418 
4 26682 27789 
5 12893 13782 
6 25512 20638 
27 Gy Three-Fraction 
7 17175 15945 
8 19398 21507 
9 9939 28788 
10 40746 50733 
11 15909 29841 
12 20943 8328 
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Grid size for each patient was the same for both FF and FFF plans and was scaled 
such that the dose calculated included the entire scanned patient volume. Grid resolution 
was 2.5 mm for all patients and plans. Grid sizes for each patient is listed below in Table 
3-6.  
 
Table 3-6: Dose grid size (pixels) 
 Size (Pixel) 
Patient ID Width Height 
1 149 100 
2 220 113 
3 143 108 
4 146 98 
5 147 97 
6 138 103 
7 167 96 
8 181 111 
9 199 113 
10 217 111 
11 210 107 
12 138 96 
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Heterogeneity index (HI) was calculated for each plan as the ratio of highest dose 
received by 5% of the PTV to lowest dose received by 95% of the PTV53 and is shown 
below in Table 3-7. 
 
Table 3-7: Heterogeneity Index for all plans 
Heterogeneity Index 
Patient ID FF FFF 
1 1.57 1.96 
2 1.65 1.63 
3 2.03 1.83 
4 2.01 1.85 
5 1.51 1.78 
6 1.59 1.63 
7 1.74 1.71 
8 1.58 1.53 
9 2.13 2.18 
10 1.92 2.07 
11 1.91 1.93 
12 1.41 1.39 
 
 
 
 
 
 
 
 
 
 
33 
 
 Field size varied and was dependent on the size of the CTV. Jaws were 
collimated such that there was a 5 mm margin around the CTV on all sides. Average 
field size for each plan is summarized below. 
 
Table 3-8: Average field sizes (cm) 
Average Field Size 
  FF FFF 
Patient ID X Y X Y 
1 10.1 9.9 10.2 10.0 
2 8.6 4.6 8.0 4.5 
3 6.6 6.2 6.4 6.2 
4 6.4 3.6 6.2 8.0 
5 10.0 13.0 6.4 4.6 
6 10.5 5.0 10.4 5.1 
7 7.3 4.4 7.1 4.5 
8 4.4 3.9 4.4 3.9 
9 8.3 3.8 8.3 3.8 
10 8.3 8.8 7.9 8.9 
11 5.7 5.5 5.4 4.9 
12 9.2 6.8 9.1 6.8 
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4  DISCUSSION 
 
4.1 – General Discussion 
We compared penumbral width as well as penumbral and out-of-field dose for FF 
and FFF beams using dose profiles obtained in a 3D water phantom from the Varian 
Standard Beam Data. Our results indicate that there is a statistically significant (p < 0.05) 
difference between FF and FFF beams in penumbral width and dose. This reduction 
tended to be more exaggerated at smaller field sizes and at shallower depths with larger 
field sizes tending towards increased penumbral dose and width for FFF beams 
compared with FF beams. That smaller field sizes tend to show more benefit from FFF 
beams is notable, as the trend towards highly-modulated treatment techniques (IMRT 
and SBRT) translates to field sizes overall growing smaller. This potential for reduction 
in normal tissue dose is an important factor to be considered in treatment planning, 
particularly for targets in close proximity to critical OAR.  
It is important to note, however, that the absolute difference in penumbral width 
was quite small. At no field size or depth did the difference exceed 0.3 mm. This 
observation suggests that the clinical benefits of FFF over FF, with respect to dose fall 
off, may in fact be quite minimal. Additionally, the difference in penumbral dose 
determined here represents only the difference in dose relative to the central axis at five 
points (2 mm, 5 mm, 10 mm, 30 mm, and 50 mm from the field edge). As such, the 
actual reduction in penumbral dose may be even smaller. 
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Treatment plans utilizing both FF and FFF beams were developed for 12 patients 
with spinal metastases in the cervical, thoracic, and lumbar regions. For each patient 
GTV Dmin was extracted and compared between the FF and FFF plans. Improvement in 
GTV Dmin was seen in approximately half of the patients while the other half saw either 
no improvement or a reduction in Dmin. The overall difference in GTV Dmin was 
deemed to be statistically insignificant by Wilcoxon Signed Rank Test. 
The differences in treatment delivery time are pronounced in that FFF plans had 
overall shorter beam on times compared with FF plans in all but a single case (Patient 
12). The potential benefit of this outcome for patients cannot be overstated, as patients 
with spinal metastases often present with pain and motor dysfunction and find it difficult 
to lie still on the treatment couch during delivery, introducing a greater potential for 
intrafractional variation. Shorter treatment times limit that potential and improve patient 
experience and throughput 
One should note that the results of a treatment planning study may be confounded 
by several factors. Experience and ability of the planner, planning system and dose 
algorithm used, beam model, optimization parameters, beam configuration, planning 
objectives, patient positioning, segment number, time spent planning, number of 
iterations, and gross anatomy may all contribute to the quality of the plan. These factors 
make achieving a completely objective plan comparison quite difficult, as a different 
planner may create entirely different plans with the same patient population and achieve 
different results.  
A potential limiting factor of this study is the method in which the beam models 
were generated and the dose calculation algorithm that was used. The Varian Standard 
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Beam Data, from which the beam models were generated in Eclipse, were obtained using 
an ionization chamber – the poor spatial resolution inherent to this measurement in 
addition to the high dose gradient of the primary region of interest (i.e., the penumbra) 
may have a negative effect on the beam model, making accurate dose calculation 
difficult. Additionally, Acuros XB dose calculation algorithm used for this study, while 
generally quite accurate, is not as precise or accurate as a dose calculation made using 
Monte Carlo methods would be. As such, it is possible that any demonstrable differences 
between FF and FFF plans may have been confounded by these factors.  
4.2 – Conclusions 
In conclusion, the hypothesis that the use of FFF beams in SBRT treatments of 
spinal cord metastases would improve target coverage was not entirely supported. Half 
of the patients saw some benefit from FFF in terms of increased GTV Dmin, but half did 
not.  Although there was a statistically significant reduction in penumbral width and dose 
for FFF beams when compared with FF beams, this difference was in absolute terms 
quite minute. All but one patient had shorter beam-on times with FFF beams compared 
to FF beams. Treatment plans developed for patients with spinal metastases using FFF 
beams were equivalent to those developed using traditional FF beams when dose to the 
spinal cord or cauda equina was kept within 5% between FF and FFF plans.  
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4.3 – Future Work 
 
As half of the patients had improved GTV Dmin and all but one had reduced delivery 
times with plans generated using FFF beams, it is possible that certain specific patients 
derive more benefits from FFF over others. Future work on this project will likely 
include multivariate analysis on a much larger patient population in order to determine 
what factors would indicate that a patient would be better served with a plan generated 
using FFF. Factors that would be investigated may include tumor size, shape, location, 
pathology, patient anatomy, treatment history, etc.  
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5  APPENDIX 
 
5.1 – Individual Patient Plans 
 
 
 
Figure 5-1: Patient 1 axial isodose images. Top: FF Plan, Bottom: FFF Plan 
39 
 
 
 
Figure 5-2: Patient 1 coronal isodose images. Top: FF Plan, Bottom: FFF Plan 
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Figure 5-3: Patient 1 sagittal isodose images. Top: FF Plan, Bottom: FFF Plan 
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Figure 5-4: Patient 1 DVH 
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Figure 5-5: Patient 2 axial isodose images. Top: FF Plan, Bottom: FFF Plan 
  
43 
 
 
 
 
Figure 5-6: Patient 2 coronal isodose images. Top: FF Plan, Bottom: FFF Plan 
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Figure 5-7: Patient 2 sagittal isodose images. Top: FF Plan, Bottom: FFF Plan 
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Figure 5-8: Patient 2 DVH 
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Figure 5-9: Patient 3 axial isodose images. Top: FF Plan, Bottom: FFF Plan  
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Figure 5-10: Patient 3 coronal isodose images. Top: FF Plan, Bottom: FFF Plan  
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Figure 5-11: Patient 3 sagittal isodose images. Top: FF Plan, Bottom: FFF Plan 
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Figure 5-12: Patient 3 DVH 
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Figure 5-13: Patient 4 axial isodose images. Top: FF Plan, Bottom: FFF Plan, Bottom: Plan 
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Figure 5-14: Patient 4 coronal isodose images. Top: FF Plan, Bottom: FFF Plan, Bottom: Plan 
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Figure 5-15: Patient 4 sagittal isodose images. Top: FF Plan, Bottom: FFF Plan 
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Figure 5-16: Patient 4 DVH 
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Figure 5-17: Patient 5 axial isodose images. Top: FF Plan, Bottom: FFF Plan 
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Figure 5-18: Patient 5 coronal isodose images. Top: FF Plan, Bottom: FFF Plan 
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Figure 5-19: Patient 5 sagittal isodose images. Top: FF Plan, Bottom: FFF Plan 
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Figure 5-20: Patient 5 DVH 
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Figure 5-21: Patient 6 axial isodose images. Top: FF Plan, Bottom: FFF Plan  
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Figure 5-22: Patient 6 coronal isodose images. Top: FF Plan, Bottom: FFF Plan 
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Figure 5-23: Patient 6 sagittal isodose images. Top: FF Plan, Bottom: FFF Plan 
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Figure 5-24: Patient 6 DVH 
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Figure 5-25: Patient 7 axial isodose images. Top: FF Plan, Bottom: FFF Plan 
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Figure 5-26: Patient 7 coronal isodose images. Top: FF Plan, Bottom: FFF Plan 
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Figure 5-27: Patient 7 sagittal isodose images. Top: FF Plan, Bottom: FFF Plan 
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Figure 5-28: Patient 7 DVH 
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Figure 5-29: Patient 8 axial isodose images. Top: FF Plan, Bottom: FFF Plan  
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Figure 5-30: Patient 8 coronal isodose images. Top: FF Plan, Bottom: FFF Plan 
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Figure 5-31: Patient 8 sagittal isodose images. Top: FF Plan, Bottom: FFF Plan 
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Figure 5-32: Patient 8 DVH 
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Figure 5-33: Patient 9 axial isodose images. Top: FF Plan, Bottom: FFF Plan, Bottom: Plan 
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Figure 5-34: Patient 9 coronal isodose images. Top: FF Plan, Bottom: FFF Plan, Bottom: Plan 
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Figure 5-35: Patient 9 sagittal isodose images. Top: FF Plan, Bottom: FFF Plan, Bottom: Plan 
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Figure 5-36: Patient 9 DVH 
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Figure 5-37: Patient 10 axial isodose images. Top: FF Plan, Bottom: FFF Plan  
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Figure 5-38: Patient 10 coronal isodose images. Top: FF Plan, Bottom: FFF Plan 
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Figure 5-39: Patient 10 sagittal isodose images. Top: FF Plan, Bottom: FFF Plan 
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Figure 5-40: Patient 10 DVH 
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Figure 5-41: Patient 11 axial isodose images. Top: FF Plan, Bottom: FFF Plan 
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Figure 5-42: Patient 11 coronal isodose images. Top: FF Plan, Bottom: FFF Plan 
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Figure 5-43: Patient 11 sagittal isodose images. Top: FF Plan, Bottom: FFF Plan 
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Figure 5-44: Patient 11 DVH 
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Figure 5-45: Patient 12 axial isodose images. Top: FF Plan, Bottom: FFF Plan, Bottom: Plan  
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Figure 5-46: Patient 12 coronal isodose images. Top: FF Plan, Bottom: FFF Plan 
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Figure 5-47: Patient 12 sagittal isodose images. Top: FF Plan, Bottom: FFF Plan 
 
85 
 
 
Figure 5-48: Patient 12 DVH 
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5.2 – Dose to Water vs. Dose to Medium 
 
 
Dose was calculated as dose to medium rather than dose to water; it should be noted 
that there exist minor differences between these two calculation methods, as 
demonstrated below in Figure 2-3. The difference between dose to medium and dose to 
water has been shown to differ by as little as 1.0% for soft tissue and 10% for cortical 
bone54. Dose to water has been the historical method of dose calculation due to how 
linacs are typically calibrated; nevertheless, accurate methods of computing absorbed 
dose to medium offer a more realistic view of how dose is deposited in the patient. 
Therefore, we chose to forego dose to water calculation and instead used dose to medium 
for this study.  
 
Figure 5-49: DVH for Dose to Medium vs. Dose to Water. Dose to Water is indicated with triangles; dose to medium with 
squares. Magenta, yellow, and red represent cauda equina, CTV, and GTV, respectively. 
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